EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

Dorsa Sadat Kiaei iD, Maxime Caru iD, Valérie Larouche, Emma Clini iD, Deepika Pugalenthi Saravanan, Sarah Lippé iD, Yves Théoret iD, Jean-Claude Décarie iD, Uri Tabori iD, Cynthia Hawkins iD, Benjamin Ellezam iD, Luis H Ospina iD und 23 weitere

Neuro-Oncology · 01.09.2026 · 28 (9) · 2279-2288

DOI: 10.1093/neuonc/noag112 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 19.05.2026. Verfasst von Dorsa Sadat Kiaei und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neurofibroma, Plexiform, Neurofibromatosis 1, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, CHU Sainte-Justine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plexiform neurofibromas (PNs) are observed in up to 50% of patients with neurofibromatosis type 1 (NF1). Trametinib has been used widely to treat PNs but limited data has been reported on its efficacy within a clinical trial. We conducted a phase 2 trial with trametinib for patients with NF1 and inoperable PNs.

Methods

Patients with NF1 and inoperable PNs aged ≥1 month to ≤25 years when starting trametinib were eligible. Patients received trametinib once daily orally continuously for a maximum of 18 cycles of 28 days. Patients completed patient-reported outcome measures. Response evaluations were performed after cycle 3, 6, 12 and at the end of treatment and then every 6 months. The PN volumes were centrally quantified using a semi-automatic 3D segmentation method.

Results

Forty-six patients were recruited. The median age was 11.1 years (range 0.7-19.8). The median baseline tumor volume was 104.6 ml (range 16.3 to 650.1 ml). Volumetric assessment demonstrated an overall response rate (volume decrease of ≥20%) in 47.8% (22/46) of patients. Median volume change was −19.3% (range −80.5 to 3.5). Forty-one patients (89.1%) completed the planned treatment. The 3 years progression free survival and the event free survival were respectively 73.1% (95% CI 53.3%-85.5%) and 47.1% (95% CI 28.8-63.5).

Conclusions

We report outcomes and volumetric response of PNs treated with trametinib within a phase 2 trial. Based on these results, trametinib is effective and overall well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeurofibroma, PlexiformNeurofibromatosis 1Protein Kinase InhibitorsPyridonesPyrimidinonesAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleYoung AdultFollow-Up StudiesPrognosisSurvival Rate

Stichwörter der Autor:innen

MEK inhibitorclinical trialneurofibromatosis type 1plexiform neurofibromatrametinib

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsPyridonesPyrimidinonestrametinib

Autor:innen und Institutionen

  • Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, Canada.
  • Department of Pediatrics, Division of Hematology and Oncology, Pennsylvania State Health Children's Hospital, Hershey, Pennsylvania, USA.
  • Department of Pediatrics, Division of Hematology-Oncology, CHU de Québec-Université Laval, Québec, Canada.
  • Department of Psychology, Université de Montréal, Montréal, Canada.
  • Centre de recherche Azrieli, CHU Sainte-Justine, Montreal, Canada.
  • Department of Pharmacology, CHU Sainte Justine, Montreal, Canada.

ORCID-Profile: Dorsa Sadat Kiaei, Maxime Caru, Emma Clini, Sarah Lippé, Yves Théoret, Jean-Claude Décarie, Uri Tabori, Cynthia Hawkins, Benjamin Ellezam, Luis H Ospina, Léandra Desjardins, Marie-Élaine Métras, Karim Estephan, Stéphanie Vairy, Éric Bouffet, Vijay Ramaswamy, Juliette Hukin, Tiffany Rent, Craig Erker, Nada Jabado, Mathieu Dehaes, Sébastien Perreault

Förderung

  • CIHR
  • CHU Sainte-Justine

Zitieren

APA

Sadat Kiaei, D., Caru, M., Larouche, V., Clini, E., Pugalenthi Saravanan, D., Lippé, S., Théoret, Y., Décarie, J. C., Tabori, U., Hawkins, C., Ellezam, B., Ospina, L. H., Desjardins, L., Métras, M. É., Sultan, S., Cantin, É., Routhier, M. È., Mailloux, C., Bertrand, M. C., …, & Perreault, S. (2026). TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology, 28(9), 2279-2288. https://doi.org/10.1093/neuonc/noag112

Vancouver

Sadat Kiaei D, Caru M, Larouche V, Clini E, Pugalenthi Saravanan D, Lippé S, et al. TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology. 2026;28(9):2279-2288. doi:10.1093/neuonc/noag112

BibTeX
@article{SadatKiaei2026,
  author = {Sadat Kiaei, Dorsa and Caru, Maxime and Larouche, Valérie and Clini, Emma and Pugalenthi Saravanan, Deepika and Lippé, Sarah and Théoret, Yves and Décarie, Jean-Claude and Tabori, Uri and Hawkins, Cynthia and Ellezam, Benjamin and Ospina, Luis H and Desjardins, Léandra and Métras, Marie-Élaine and Sultan, Serge and Cantin, Édith and Routhier, Marie-Ève and Mailloux, Chantal and Bertrand, Marie-Claude and Estephan, Karim and McKeown, Tara and Vairy, Stéphanie and Legault, Geneviève and Renzi, Samuele and Bouffet, Éric and Ramaswamy, Vijay and Coltin, Hallie and Lafay-Cousin, Lucie and Hukin, Juliette and Alves, Mélanie and Rent, Tiffany and Erker, Craig and Jabado, Nada and Dehaes, Mathieu and Perreault, Sébastien},
  title = {TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {2279--2288},
  doi = {10.1093/neuonc/noag112}
}
Kostenlos starten →